Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

On Sunday 25 April, World Malaria Day, the Developing Paediatric Primaquine (DPP) project will launch its website. DPP will produce children-appropriate primaquine doses that could both cut malaria deaths in vulnerable African children by blocking transmission of P. falciparum malaria and reduce P. vivax malaria more widely.

Two researchers working in a lab © Photo courtesy of the Laboratory of Industrial & Pharmaceutical Technology of the University of Bordeaux (France)

Logo for the Developing Paediatric Primaquine (DPP) projectThe Developing Paediatric Primaquine project will develop and prequalify primaquine in tablet strengths appropriate for children and develop optimal primaquine regimens so that one tablet equals one dose.

Primaquine has two key roles in malaria elimination: the radical cure of Plasmodium vivax and P. ovale, and blocking P. falciparum transmission. DPP’s research includes granule work, taste masking, a bioequivalence study and two field trials: one of vivax radical cure (Ethiopia) and a study of single low dose primaquine to block falciparum malaria transmission (Burkina Faso).

Although children aged under 5 years are the most vulnerable group affected by malaria, accounting for 67% (274,000) of all malaria deaths worldwide in 2019, there are currently no paediatric primaquine tablets or kids-friendly formulations approved by a stringent regulatory authority or prequalified by WHO. This is a major obstacle for global malaria elimination – particularly in Africa, home to 94% of malaria cases and deaths, but also countries with high burdens of P. vivax.  

Supported by a grant from EDCTP2 (the European and Developing Countries Clinical Trials Partnership), an African-European institutional consortium, the Developing Paediatric Primaquine (DPP) project will develop and prequalify primaquine in a range of tablet strengths appropriate for children (2.5, 3.75, and scored 5, 7.5 and 15 mg) and develop optimal primaquine regimens so that one tablet equals one dose.
Once the bioequivalence of the 15 mg generic tablet is confirmed and the biowaiver for the lower strengths is granted, the full range of primaquine tablets can be prequalified – permitting their use by national malaria control programmes – with potentially a big impact on global malaria.

“Getting these child-appropriate primaquine doses prequalified by the WHO could have a massive impact on malaria elimination and malaria deaths in African children. WHO prequalification would allow the child-appropriate doses to be distributed widely by malaria control programmes,” explained project coordinator Dr Bob Taylor of the Mahidol Oxford Tropical Medicine Research Unit (MORU).

To optimise the drug formulations and make the pills palatable to children, the DPP project will perform sensory studies to identify the best kid-friendly aromas to mask the bitter taste of primaquine and, in parallel, validate the use of these new tablets by conducting clinical and pharmacokinetic studies for curing P. vivax in Ethiopia and blocking the transmission of P. falciparum malaria in Burkina Faso. Moreover, granule formulations and bespoke packaging are new concepts that will also be developed to make primaquine more user-friendly and so improve adherence.

“Granules are really the most convenient form for small children, and we hope to obtain additional funds in anticipation that the WHO will call officially for primaquine granules. In the meantime, packaging flavoured primaquine tablets for children is the way to go,” said DPP project manager Dr Julie Nguyen Ngoc Pouplin, who is based at Réseau Médicaments et Développement (ReMeD).

On Sunday 25 April, World Malaria Day, the Developing Paediatric Primaquine project will launch its website. Intended for a broad audience, including malariologists, policy makers, regulatory authorities and curious members of the public, the site will present the DPP project roadmap, its different work packages and consortium partners, and provide updates on project progress.

The Developing Paediatric Primaquine project is part of the EDCTP2 programme supported by the European Union

Similar stories

Congratulations to Professor Sir David Warrell, appointed Knight Commander of the Order of St Michael and St George!

David Warrell, MORU founding director, has been appointed by the Queen ‘Knight Commander of the Order of St Michael and St George for services to global Health Research and Clinical Practice’. Please join us in congratulating Sir David on receiving this richly deserved high honour!

Laos’ first Pint of Science: warty newts, COVID, AI for Instagram, and more!

Organised by a grass-root community of thousands of scientists across the world, Pint of Science 2022 allows researchers in 25 countries and over 800 cities to share their latest findings with lay folk in interesting, informal settings. Lao PDR joined the global Pint of Science family on Monday 9 May, when the first-ever Pint of Science Laos kicked off!

Patient recruitment on track in Oxford-led DeTACT trial of safe, effective drug combinations to prevent the spread of artemisinin and multi-drug resistant malaria in Africa

Today is World Malaria Day. The global fight against malaria is at a critical point. No new antimalarial drugs are expected in the near future, and if multi-drug resistant falciparum malaria becomes established in East Africa and spreads to other parts of Africa, millions will be at risk of drug-resistant malaria infection and death. The development of triple artemisinin-based combination therapies aims to prevent or delay the emergence of artemisinin and multi-drug resistant malaria in Africa.

PRIORITISE study team publishes results, now seeks partners

In regions where few people have received Covid-19 vaccines, health systems remain vulnerable to surges in SARS-CoV-2 infections. During the delta-wave of COVID-19 in India, for example, healthcare facilities and staff across the country struggled to cope with the surge in the number of cases of COVID-19 due to a shortage of hospital beds for people with severe cases, plus shortages of medicines and limited human resources.

Under the Mask, drama film based on testimonies of tuberculosis patients

In 2022, tuberculosis (TB) remains a major global health problem, particularly in developing countries. On the Thai-Myanmar border, TB is an important problem among migrants, a vulnerable, very mobile population, with unstable, often difficult living conditions, insecure incomes, and poor access to health services.

TACT-CV study shows artemether–lumefantrine plus amodiaquine an effective treatment for multidrug-resistant malaria in GMS

A triple artemisinin-based combination therapy (TACT) of artemether-lumefantrine plus amodiaquine (AL+AQ) for uncomplicated falciparum malaria in areas with a high prevalence of artemisinin resistance is a well-tolerated, effective treatment for multidrug-resistant parasites, say a team of MORU-led researchers.